Subsidiary FORUS Therapeutics Inc. Announces Health Canada Approval of BESREMi (Ropeginterferon alfa-2b) for Adult Polycythemia Vera (PV)

Date of Announcement: July 4, 2026 Date of Statement: July 3, 2026 Time of Statement: 15:10:26 Company Code: 6446 Company Name: PharmaEssentia Subject: The company announces on behalf of its subsidiary, FORUS Therapeutics Inc., that the new drug BESREMi (ropeginterferon alfa-2b) has been approved by Health Canada for use in adult polycythemia vera (PV). Applicable Clause: Clause 10 Factual Date: July 2, 2026

Details: 1. Factual Date: 07/02/2026 2. Name or Code of the New Drug: BESREMi (ropeginterferon alfa-2b, also known as P1101) 3. Indication: Treatment of adult patients with polycythemia vera (PV). 4. All Planned Development Stages: Not applicable. 5. Current Development Stage (please specify whether application submitted/approved/not approved; if not approved, describe risks and countermeasures; also include future business direction and cumulative R&D expenses): (1) Status regarding regulatory submission/approval/rejection, results of clinical trials (including interim analyses), or other significant events affecting drug development: The pre-filled syringe formulation of BESREMi (ropeginterferon alfa-2b) 500 mcg/mL solution for injection has been approved by Health Canada for the treatment of adult polycythemia vera (PV). (2) Risks and countermeasures if not approved by the competent authority, clinical trial results lack statistical significance, or other major events occur: Not applicable. (3) Future business direction following approval by the competent authority, statistically significant clinical trial results, or other major events: FORUS Therapeutics Inc. will officially launch sales and marketing activities for ropeginterferon alfa-2b in Canada as planned. (4) Cumulative R&D expenses incurred: To protect corporate and investor interests and in consideration of future marketing strategies, cumulative R&D expenses will not be disclosed at this time. 6. Next Development Stage (expected completion date and anticipated obligations): (1) Expected completion date: Not applicable. (2) Anticipated obligations: None. 7. Market Overview: Polycythemia vera (PV) is a type of myeloproliferative neoplasm (MPN). While excessive red blood cell production is most prominent, white blood cells and platelets are also elevated in most cases. PV patients face a high risk of cardiovascular complications such as thrombosis and embolism, and may progress to secondary myelofibrosis (MF) or acute myeloid leukemia (AML), affecting survival and quality of life. Market research estimates approximately 17,000 PV patients in Canada. Current clinical treatments include phlebotomy, hydroxyurea (HU), interferon, and JAK2 inhibitors. 8. Other Matters to be Disclosed: Ropeginterferon alfa-2b is a next-generation, long-acting interferon independently developed and manufactured by the company. It has now been approved in approximately 50 countries worldwide, including major pharmaceutical markets such as the United States, Japan, China, and the European Union, for the treatment of adult PV patients. 9. Drug development involves long timelines, high investment costs, and no guarantee of success, which may expose investors to risks. Investors are advised to make careful and prudent decisions.